ZHU ZHENGLUN has a total of 46 patent applications. It decreased the IP activity by 12.0%. Its first patent ever was published in 2007. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are INSERM INSTITUTE NATIONAL DE LA SANTE ET DE LA RECH MEDICALE, NAT INST OF BIOMEDICAL INNOVATION HEALTH & NUTRITION and OSTEONEUROGEN.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 12 | |
#2 | EPO (European Patent Office) | 8 | |
#3 | WIPO (World Intellectual Property Organization) | 6 | |
#4 | China | 5 | |
#5 | Singapore | 4 | |
#6 | Canada | 3 | |
#7 | Hong Kong | 2 | |
#8 | Republic of Korea | 2 | |
#9 | Australia | 1 | |
#10 | Chile | 1 | |
#11 | Hungary | 1 | |
#12 | Israel | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Measuring microorganism processes | |
#4 | Microorganisms | |
#5 | Analysing materials | |
#6 | Peptides | |
#7 | Enzymes |
# | Name | Total Patents |
---|---|---|
#1 | Zhu Zhenglun | 46 |
#2 | Gao Hong | 26 |
Publication | Filing date | Title |
---|---|---|
EP3601539A1 | Methods of treating neoplastic diseases | |
US2019085336A1 | Treatment and diagnosis of inflammatory disorders | |
SG10201913133WA | Method of modifying macrophage differentiation and immunity | |
EP2984165A1 | Homeobox transcription factor ventx regulates differentiation and maturation of human dendritic cells | |
WO2012170979A1 | Human homeobox gene ventx and macrophage terminal differentiation and activation, compositions and methods thereof | |
CN102575250A | Treatment and diagnosis of immune disorders | |
EP1991246A2 | Treatment of development-related disorders |